Last reviewed · How we verify

PTC+Pertuzumab — Competitive Intelligence Brief

PTC+Pertuzumab (PTC+Pertuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + investigational agent combination. Area: Oncology.

phase 3 Monoclonal antibody + investigational agent combination HER2 (pertuzumab component); PTC target unknown Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PTC+Pertuzumab (PTC+Pertuzumab) — The Netherlands Cancer Institute. PTC+Pertuzumab combines a PTC (likely a protein tyrosine kinase inhibitor or similar agent) with pertuzumab, a HER2-targeting monoclonal antibody that blocks HER2 dimerization to inhibit tumor growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PTC+Pertuzumab TARGET PTC+Pertuzumab The Netherlands Cancer Institute phase 3 Monoclonal antibody + investigational agent combination HER2 (pertuzumab component); PTC target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + investigational agent combination class)

  1. The Netherlands Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PTC+Pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/ptc-pertuzumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: